Tempus, a company focused on personalized oncology care, collects and analyzes large-scale databases of molecular and clinical information to support physicians treating cancer patients.
Under the agreement, Tempus will use its Tempus O platform to structure patient data from Vanderbilt-Ingram Cancer Center’s EHR. The company will also provide the cancer center with next generation sequencing and analysis services to identify actionable gene alterations.
“Collaborating with Tempus will allow the Vanderbilt-Ingram team to gain a deeper understanding of a patient’s cancer and its genetic and molecular drivers, with a goal of improving patient outcomes,” said Jennifer Pietenpol, PhD, director of the Vanderbilt-Ingram Cancer Center.
More articles on data analytics & precision medicine:
Microsoft, Google venture arms invest in genomic information startup DNAnexus
Baptist Health South Florida taps health tech startup for precision cancer care
4 questions with PotentiaMetrics CEO Robert Palmer on personalized healthcare
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
